The clinical relevance of plasma CD147/basigin in biopsy-proven kidney diseases
Precise understanding of kidney disease activity is needed to design therapeutic strategies. CD147/basigin is involved in the pathogenesis of acute kidney injury and renal fibrosis through inflammatory cell infiltration. The present study examined the clinical relevance of CD147 in biopsy-proven kidney diseases that lead to the progression of chronic kidney disease.
Kidney biopsy specimens and plasma and urine samples were obtained from patients with kidney diseases, including IgA nephropathy (IgAN), Henoch–Schönlein purpura nephritis (HSPN), diabetic kidney disease (DKD), focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN), who underwent renal biopsy between 2011 and 2014. Plasma and urinary CD147 levels were measured and evaluated for their ability to reflect histological features. Disease activity of IgAN tissues was evaluated according to the Oxford classification and the Japanese histological grading system.
In biopsy tissues, CD147 induction was detected in injured lesions representing renal inflammation. Plasma CD147 values correlated with eGFR in patients with inflammation-related kidney diseases such as IgAN, HSPN, and DKD. Particularly in IgAN patients, plasma CD147 levels were correlated with injured regions comprising more than 50% of glomeruli or with tubular atrophy/interstitial injury in biopsy tissues. Proteinuria showed a closer correlation with urinary values of CD147 and L-FABP. Of note, plasma and urinary CD147 levels showed a strong correlation with eGFR or proteinuria, respectively, only in DKD patients.
Evaluation of plasma and urinary CD147 levels might provide key insights for the understanding of the activity of various kidney diseases.
KeywordsCD147 Inflammation Proteinuria
The authors would like to thank Norihiko Suzuki, Naoko Asano, and Yuriko Sawa for their excellent technical assistance, and Hitomi Aoyama for secretarial assistance.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interests.
This study was conducted according to the principles of the Declaration of Helsinki, the Japanese National Ethical Guidelines, and the institutional review boards of Nagoya University Hospital and affiliated hospitals (Approval Number, 1135).
All patients provided written, informed consent to participate in the study.
Supported by a Grant-in-Aid for Nephrology Research from the Ministry of Health, Labor and Welfare of Japan (90584681 to T. K.).
- 2.Kidney Disease: Improving global outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1–S130.Google Scholar
- 6.Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173–81.CrossRefPubMedGoogle Scholar